Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verteporfin

Next Previous
Drug Profile

Verteporfin

Alternative Names: Benzoporphyrin derivative monoacid ring A; BPD; BPD-MA; CL 315555; CL 315585; CL 318952; Everteporfine; Verteporfin for injection - Novartis; Visudine; Visudyne

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of British Columbia
  • Developer Bausch Health Companies; Valeant Pharmaceuticals International
  • Class Antineoplastics; Eye disorder therapies; Porphyrins; Small molecules
  • Mechanism of Action Immunomodulators; Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Choroidal neovascularisation; Central serous chorioretinopathy; Age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Age-related macular degeneration; Choroidal neovascularisation
  • No development reported Central serous chorioretinopathy
  • Discontinued Breast cancer; Coronary artery restenosis; Diabetic macular oedema; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 18 Jul 2018 Verteporfin licensed to Cheplapharm Arzneimittel worldwide, except for USA
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Central serous chorioretinopathy in Canada (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top